Following these proceedings, Ladenburg Thalmann initiated its Aptevo Therapeutics Inc [APVO] rating to a Buy in a research note published recently.
Price Performance Review of APVO
On Tuesday, Aptevo Therapeutics Inc [NASDAQ:APVO] saw its stock jump 9.08% to $0.69. Over the last five days, the stock has lost -33.33%. Aptevo Therapeutics Inc shares have fallen nearly -83.91% since the year began. Nevertheless, the stocks have fallen -97.57% over the past one year. While a 52-week high of $51.06 was reached on 01/07/25, a 52-week low of $0.60 was recorded on 04/21/25. SMA at 50 days reached $2.2800, while 200 days put it at $7.6103.
Levels Of Support And Resistance For APVO Stock
The 24-hour chart illustrates a support level at 0.6289, which if violated will result in even more drops to 0.5645. On the upside, there is a resistance level at 0.7589. A further resistance level may holdings at 0.8245. The Relative Strength Index (RSI) on the 14-day chart is 30.24, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.3650, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.01%. Stochastics %K at 1.73% indicates the stock is a buying.
How much short interest is there in Aptevo Therapeutics Inc?
A steep rise in short interest was recorded in Aptevo Therapeutics Inc stocks on 2025-03-31, growing by 0.33 million shares to a total of 0.39 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 60058.0 shares. There was a rise of 84.46%, which implies that there is a positive sentiment for the stock.
